Document is current
Any future updates will be listed below
-
Authors
He, Xinyi
Shi, Mengting
Zhang, Lin
Zhan, Jianhua
Liu, Jiaqing
Sun, Dongchen
Chen, Zihong
Hong, Shaodong
Zhang, Yaxiong
Chen, Gang
Zhao, Shen
Zhou, Ting
Fang, Wenfeng
Zhao, Yuanyuan
Huang, Yan
Zhou, Caicun
Yang, Yunpeng
Zhang, Li
Zhou, Huaqiang
-
Funding
Funding for this research was provided by:
Innovent Biologics
National Natural Science Foundation of China (82241232, 82102864)
Guangzhou Basic and Applied Basic Research Foundation (2024A04J4082)
Young Talents Program of Sun Yat-sen University Cancer Center (YTP-SYSUCC-0096)
- License Information
-
More Information
Article History
Received: 31 March 2025
Accepted: 25 July 2025
First Online: 27 August 2025
Declarations
:
: This study was conducted in full compliance with the ethical principles of the Declaration of Helsinki. The study protocol received approval from the Ethics Committee of Sun Yat-sen University Cancer Center (Approval No. A2018-025–01). All enrolled participants provided written informed consent.
: Not Applicable.
: Li Zhang: Consulting or Advisory Role: AstraZeneca; Speakers’ Bureau: AstraZeneca, HenRui, Akeso Biopharma, Sichuan Biokin Pharmaceutical, China Shiyao Pharma, Roche; Research Funding: BMS (Inst), AstraZeneca (Inst), Akeso Biopharma (Inst), QiLu Pharmaceutical (Inst), Chia Tai Tianqing Pharmaceutical Group (Inst), Sichuan Kelun-Biotech Biopharmaceutical (Inst), Sichuan Biokin Pharmaceutical (Inst), Innovent Biologics, Inc. No other potential conflicts of interest were reported.
